cas 2252403-82-8|| where to buy 7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

Product Name:7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

IUPAC Name:7-chloro-6-fluoro-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-1H,2H,3H,4H-pyrido[2,3-d]pyrimidine-2,4-dione

: CAS：2252403-82-8; Molecular Formula：C16H14ClFN4O2; Purity：95%+

Packing Unit	Available Stock	Price($)
CM337558-100g	in stock	Žǟĳĳ
CM337558-500g	in stock	ĳǸřħ
CM337558-1000g	in stock	ƚřřř

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:2252403-82-8; Molecular Formula:C16H14ClFN4O2; Melting Point:-; Smiles Code:O=C1N(C2=C(C)C=CN=C2C(C)C)C3=NC(Cl)=C(F)C=C3C(N1)=O; Density:

: Catalog Number:CM337558; Molecular Weight:348.76; Boiling Point:; MDL No:; Storage:Keep in a tight container and store at abient temperature

: Sotorasib; Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.